Connect with us


Group renews Ivermectin drive

We did the work that the medical authorities failed to do.



Immediate global use of the anti-parasite drug Ivermectin will end the Covid-19 pandemic, a group of medical and scientific experts said.

The statement came after reviewing published peer-reviewed studies, manuscripts, expert meta-analyses, and epidemiological analyses of regions with Ivermectin distribution efforts.

The Front Line Covid-19 Critical Care Alliance (FLCCC) said all its research has shown that Ivermectin is effective prophylaxis and treatment for Covid-19.

The medical experts include three US government senior scientists who published their peer review in the American Journal of Therapeutics and said the research is the most comprehensive review of the available data taken from clinical, in vitro, animal, and real-world studies.

“We did the work that the medical authorities failed to do. We conducted the most comprehensive review of the available data on Ivermectin,” said Pierre Kory, M.P.A., MD, president, and chief medical officer of the FLCCC. “We applied the gold standard to qualify the data reviewed before concluding that Ivermectin can end this pandemic.”

A focus of the manuscript was on the 27 controlled trials available in January 2021, 15 of which were randomized controlled trials (RCT), the preferred trial of the World Health Organization, US National Institutes of Health, and the European Medicines Agency. Consistent with numerous meta-analyses of Ivermectin RCT since published by expert panels from the U.K., Italy, Spain, and Japan, they found a considerable, statistically significant reduction in mortality, time to recovery, and viral clearance Covid-19 patients treated with Ivermectin.

To evaluate the efficacy of Ivermectin in preventing Covid-19, three RCT and five observational controlled trials, including almost 2,500 patients, reported that Ivermectin significantly reduces the risk of contracting Covid-19 when used regularly.

The experts said that meta-analyses based on 18 randomized controlled treatment trials of Ivermectin in Covid-19 had found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.

In addition, numerous controlled prophylaxis trials report significantly reduced risks of contracting Covid-19 with the regular use of Ivermectin. Finally, the many examples of Ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of Covid-19 have been identified.

Many regions around the world now recognize that Ivermectin is potent prophylaxis and treatment for Covid-19. South Africa, Zimbabwe, Slovakia, Czech Republic, Mexico, and India have approved the drug for use by medical professionals. As seen in this latest study, the results demonstrate that the Ivermectin distribution campaigns repeatedly led to “rapid population-wide decreases in morbidity and mortality”.